Outlook Therapeutics is trading 10.36% up now at $0.67, primarily supported by stronger biotechnology sentiment, with XBI up 2.06% during regular trading alongside a broader Nasdaq advance.
- No new company-specific announcement was identified for August 25, 2026.
- FDA approval of LYTENAVA on July 24 and August financing remain important background, but neither is a new catalyst today.
- The company is preparing its U.S. commercial launch.